Lilly’s tirzepatide reduces body weight in Phase III type 2 diabetes trial
The investigational therapy’s overall safety profile was consistent with the safety data measured at 52...
News
Enzychem’s EC-18 reduces occurrence of oral mucositis in Phase II trial
The therapy met the primary and secondary endpoints in the trial in chemoradiation-induced oral mucositis...
Inhibikase doses first subject in Phase Ib Parkinson’s treatment trial
The trial will evaluate the safety, pharmacokinetics and tolerability of IkT-148009 in 24 Parkinson’s patients.
Atea’s AT-527 fails to meet primary goal of Phase II Covid-19 trial
In the trial, the oral antiviral was demonstrated to be safe and well-tolerated with data...
Dermata reports Phase I data of DMT310 to treat psoriasis
Nearly 29.6% of the subjects who received DMT310 had a Physician’s Global Assessment score of...
Entasis reports positive data from Phase III Acinetobacter drug trial
SUL-DUR met the trial’s primary safety goal, attaining a statistically significant reduction in nephrotoxicity.
Valneva’s Covid-19 vaccine meets co-primary goals in Phase III trial
VLA2001 was well tolerated with a tolerability profile that is highly favourable as compared to AstraZeneca’s vaccine.
NIH reports interferon is ineffective in hospitalised Covid-19 patients
Treatment with interferon beta-1a was linked to more adverse events in Covid-19 patients needing high-flow oxygen.
Innovent’s sintilimab meets primary goal of Phase III lung cancer trial
The safety profile in the trial was consistent with already observed data from trials of sintilimab and Byvasda.
Emergent commences Phase III trial of single-dose chikungunya vaccine
The trial will have at least 3,150 healthy subjects aged 12 to 64 years enrolled at up to 49 centres in the US.
Biogen’s tofersen fails to meet primary goal in Phase III ALS trial
The company says that trends favouring tofersen were found across several secondary and exploratory measures.
